Clinical Trials Sponsored by 4Moving Biotech

Total 1811 results

4Moving Biotech

Completed

Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (LASARE)

Knee Osteoarthritis

Belgium
4Living Biotech

Withdrawn

Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb) (LEONARDO)

COVID-19 | COVID-19 Acute Respiratory Distress Syndrome

France, Bulgaria
Theratocular Biotek Co.

Recruiting

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Thailand
Sotio Biotech Inc.
SOTIO Biotech AG; SOTIO Biotech a.s.

Recruiting

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1)

Hepatocellular Carcinoma | Squamous Cell Carcinoma of the Lung | Merkel Cell Carcinoma | Myxoid/Round Cell Liposarcoma

United States
SOTIO Biotech AG
SOTIO Biotech a.s.

Active, not recruiting

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions

United States, France, Spain, Czechia
Neovii Biotech
Fresenius Biotech North America

Completed

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Ovarian Cancer

United States
Neovii Biotech
Fresenius Biotech North America

Terminated

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

Advanced Breast Cancer | Metastatic Breast Cancer

United States, Canada
Impact Biotech Ltd
Impact biotech Ltd.

Not yet recruiting

Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

Peripheral Lung Tumor
J2H Biotech

Recruiting

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

Non-alcoholic Steatohepatitis

Korea, Republic of
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China
Meccellis Biotech

Recruiting

Evaluation of a Non-cross-linked Porcine Acellular Dermal Matrix Used in Dental Surgery

Dental Surgery

France
HoHo Biotech

Recruiting

To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement.

Autoimmune Diseases | Metabolic Disease

Taiwan
Acticor Biotech

Completed

Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 (GARDEN)

COVID-19 | Acute Respiratory Distress Syndrome | ARDS | SARS-CoV Infection

France
Neovii Biotech

Completed

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Myelodysplastic Syndrome | GVHD | Adult Acute Myeloid Leukemia | Adult Acute Lymphoid Leukemia

United States, Australia
Activartis Biotech

Completed

Dendritic Cell Cancer Vaccine for High-grade Glioma (GBM-Vax)

Glioblastoma Multiforme

Austria
Trinity Biotech

Unknown

Clinical Study to Validate the Use of a New Point of Care Troponin I Test

Acute Coronary Syndrome

United States
Oncolytics Biotech

Completed

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Carcinoma, Squamous Cell of the Head and Neck

United States
Oncolytics Biotech

Completed

Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas

Malignant Glioma

United States
Neovii Biotech

Completed

Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites (SECIMAS)

Malignant Ascites Due to Epithelial Carcinoma

Germany
Facet Biotech

Withdrawn

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

Hypertension

United States
Facet Biotech

Completed

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Graft vs Host Disease

United States
Facet Biotech

Completed

Research Study in Patients With Severe Ulcerative Colitis

Ulcerative Colitis

United States
Facet Biotech

Withdrawn

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

Heart Failure, Congestive

United States
Neovii Biotech

Terminated

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

Advanced Breast Cancer | Metastatic Breast Cancer

Spain, Austria, France, Germany, Italy
Neovii Biotech

Completed

Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

Gastric Cancer | Gastric Adenocarcinoma

Germany
Global Biotech

Completed

Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.

Cerebrovascular Accident

Taiwan
SOTIO Biotech AG

Recruiting

A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Advanced Solid Tumor | Metastatic Solid Tumor

United States, Spain, Czechia, Belgium, France
SOTIO Biotech a.s.

Recruiting

Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01)

Pancreatic Cancer

United States, Belgium, Czechia, France, Spain
Impact Biotech Ltd
Impact biotech Ltd.

Active, not recruiting

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

Locally Advanced Unresectable Pancreatic Adenocarcinoma

United States
SOTIO Biotech AG

Active, not recruiting

A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

Colorectal Cancer

France, Spain, Belgium
Neovii Biotech
Fresenius Biotech North America

Completed

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Malignant Ascites

United States
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (BAH246)

T Cell Lymphoma | T Cell Prolymphocytic Leukemia | T-cell Acute Lymphoblastic Leukemia | T Cell Leukemia | T-Cell Lymphoma of CNS | T Cell Childhood ALL

China
Aurion Biotech

Recruiting

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) (CLARA)

Corneal Edema | Corneal Endothelial Dysfunction

United States, Canada
Meccellis Biotech

Recruiting

Safety and Clinical Performance of a Biological Matrix Used in Implant-based Breast Reconstruction

Breast Reconstruction Following Mastectomy

France
ElsaLys Biotech

Not yet recruiting

Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD (EiFFEL)

Steroid Refractory GVHD
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
CEN Biotech

Completed

Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus. (TINNITY)

Tinnitus

France
Aurion Biotech

Completed

A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction (Escalon)

Corneal Edema

El Salvador
Biotech Dental

Completed

Performance and Safety of Use of the "KONTACT PERIO LEVEL" Transgingival Titanium Dental Implant (KPL)

Tooth Loss | Partially Edentulous Maxilla | Partially Edentulous Mandible

France
Acticor Biotech

Completed

Acute Ischemic Stroke Interventional Study (ACTIMIS)

Acute Ischemic Stroke

France
Oncolytics Biotech

Completed

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Cinfa Biotech

Completed

Immunogenicity and Pharmacodynamic of B12019 and Neulasta® in Healthy Subjects

Healthy Volunteers

Germany
Activartis Biotech

Completed

Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood

Childhood Solid Tumor

Austria
Trinity Biotech

Completed

99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I Test

Acute Coronary Syndrome

United States
Oncolytics Biotech

Completed

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

Osteosarcoma | Leiomyosarcoma | Fibrosarcoma | Sarcoma, Synovial | Ewing Sarcoma Family Tumors | Malignant Fibrous Histiocytoma

United States
Neovii Biotech

Completed

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Gastric Cancer | Gastric Adenocarcinoma

Austria, Spain, United Kingdom, Germany
Neovii Biotech

Terminated

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Epithelial Cancer Patients

Austria, Denmark, Spain
Neovii Biotech

Completed

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Ovarian Cancer | Epithelial Ovarian Cancer

Austria, Germany
Neovii Biotech

Completed

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Bronchiectasis | Idiopathic Pulmonary Fibrosis | Cystic Fibrosis | Chronic Obstructive Pulmonary | Pulmonary Vascular Disease

United States, Australia, Austria, Canada
Facet Biotech

Completed

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

Crohn's Disease | Colitis | Digestive System Disease | Gastrointestinal Disease | Intestinal Disease

United States, Canada

Clinical Trials Sponsored by 4Moving Biotech

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations